Results 21 to 30 of about 77,084 (260)

PARP Inhibitors for Chemoprevention—Letter [PDF]

Cancer Prevention Research, 2014
We read with great optimism To and colleagues' ([1][1]) article about PARP inhibitors as effective chemopreventive strategy for treating homologous repair (HR)–deficient tumors. Their overarching conclusion stated in the discussion is that “…synthetic lethality (i.e., PARP inhibitor ...
Saswati N, Chand, Fernando F, Blanco, Masaya, Jimbo, Theodore N, Tsangaris, Massimo, Cristofanilli, Charles J, Yeo, Jordan M, Winter, Michael J, Pishvaian, Jonathan R, Brody   +8 more
openaire   +2 more sources

Effects of alcohol and PARP inhibition on RNA ribosomal engagement in cortical excitatory neurons

Frontiers in Molecular Neuroscience, 2023
We report on the effects of ethanol (EtOH) and Poly (ADP-ribose) polymerase (PARP) inhibition on RNA ribosomal engagement, as a proxy for protein translation, in prefrontal cortical (PFC) pyramidal neurons.
Harish R. Krishnan, Gian Paolo Vallerini, Hannah E. Gavin, Marina Guizzetti, Marina Guizzetti, Hooriyah S. Rizavi, Hooriyah S. Rizavi, David P. Gavin, David P. Gavin, Rajiv P. Sharma, Rajiv P. Sharma   +10 more
doaj   +1 more source

PARP Inhibitors in Prostate Cancer [PDF]

Anticancer Research, 2021
Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal, Kayanaat, Grewal, Imad A, Tabbara   +2 more
openaire   +2 more sources

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer. [PDF]

Kaohsiung J Med Sci
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhan JH, Geng JH, Ke HL, Huang SP, Jia L.   +4 more
europepmc   +2 more sources

Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer

Cells, 2020
The role and therapeutic promise of poly-ADP ribose polymerase (PARP) inhibitors in anticancer chemotherapy are increasingly being explored, particularly in adjuvant or maintenance therapy, considering their low efficacy as monotherapy agents and their ...
Shiue-Wei Lai, Oluwaseun Adebayo Bamodu, Jia-Hong Chen, Alexander TH Wu, Wei-Hwa Lee, Tsu-Yi Chao, Chi-Tai Yeh   +6 more
doaj   +1 more source

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Journal of Experimental & Clinical Cancer Research, 2018
Background Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy.
Xiaoting Lin, Dongshao Chen, Cheng Zhang, Xiaotian Zhang, Zhongwu Li, Bin Dong, Jing Gao, Lin Shen   +7 more
doaj   +1 more source

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

Journal for ImmunoTherapy of Cancer, 2021
Background Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions.
Dorota Wyczechowska, Amir A Al-Khami, Luis Del Valle, Augusto C Ochoa, Mohamed A Ghonim, Salome V Ibba, Abdelmetalab F Tarhuni, Youssef Errami, Hanh H Luu, Matthew J Dean, Ali H El-Bahrawy, Ilyes A Benslimane, A Hamid Boulares   +12 more
doaj   +1 more source

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

Haematologica, 2009
Background Aberrant or impaired repair of double-strand DNA breaks is a common feature of de novo acute myeloid leukemia and myelodysplastic syndromes.
Terry J. Gaymes, Sydney Shall, Lee J. MacPherson, Natalie A. Twine, Nicholas C. Lea, Farzin Farzaneh, Ghulam J. Mufti   +6 more
doaj   +1 more source

Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

EMBO Molecular Medicine, 2012
PARP inhibitors have been proposed as a potential targeted therapy for patients with triple‐negative (ER‐, PR‐, HER2‐negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be ...
Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord, Alan Ashworth   +6 more
doaj   +1 more source

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Journal of Experimental & Clinical Cancer Research, 2019
Background The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy.
Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti   +9 more
doaj   +1 more source